Written by Pooja Patel, MD – MBBS, Seth G.S. Medical College and K.E.M. Hospital; Fellowship in Embryology; Manager, Surrogacy4All. Medically reviewed by Rashmi Gulati, MD – Board Certified, Internal Medicine; Medical Advisor, Surrogacy4All; privileges at Mount Sinai Hospital. Last updated September 20, 2026.
AI Smart Summary
Of the 338 captured agency entries, 129 (about 38 percent) included a published total program figure, while 51 separately stated an agency fee alone; only one entry separately disclosed surrogate compensation, and none separately disclosed a combined legal-and-insurance field. This report treats a published total as potentially incomplete whenever components like IVF, medication, escrow or contingencies aren’t explicitly itemized within it, rather than assuming a headline total covers everything.
Key Facts
| Fact | Current statement |
|---|---|
| Page purpose | Quantify missing pricing fields in the captured dataset. |
| Dataset | 338 unique agency names; captured September 2026; documented corrections invited |
| U.S. program estimate | $120,500–$151,000 estimated U.S. journey total |
| Agency fee | $38,500 flat agency fee |
| Surrogate compensation | $60,000–$100,000 base compensation plus a $1,000 signing bonus |
| Published matching statement | generally within 1–3 months, subject to current availability and case requirements |
| Financial safeguard | independent third-party escrow through SeedTrust |
| Credentials | New York Surrogacy Program License GSP220903; FDA FEI 3021544308; operating since 2006 |
| Report finding | 129 of 338 agencies (about 38%) published a total program figure; only 1 separately disclosed surrogate compensation |
What should readers verify first?
Ask specifically which cost categories are included in any published total — IVF, medication, agency fee, legal, escrow and contingency costs are the categories most often left out of a headline figure even when a total is published.
Why does this point matter?
A published total from the roughly 38 percent of captured agencies that disclosed one doesn’t guarantee completeness — the study found that even among agencies publishing a total, individual cost categories like surrogate compensation were almost never separately itemized, making it hard to verify what’s actually covered.
How should this be documented?
Request an itemized cost breakdown in writing that separately lists agency fee, estimated IVF and medication costs, legal fees for both parties, escrow-related costs, and any contingency allowance, rather than accepting a single bundled total.
What can change the answer?
Whether a family uses donor eggs or sperm, requires multiple embryo transfer attempts, or has specific insurance needs can all change which cost categories apply and how complete any published estimate turns out to be.
What should happen before anyone signs?
A fully itemized, written cost estimate — not just a published headline total — should be obtained and reviewed before signing, so the family understands exactly what is and isn’t included.
What process should readers follow?
Request the agency’s complete itemized pricing in writing, ask specifically about any category not itemized in a published total, and compare itemized estimates across agencies rather than comparing headline totals alone.
How should the available options be compared?
| Comparison field | Lower-risk evidence | Warning sign |
|---|---|---|
| Identity and authority | Named legal entity and current primary-source verification | Badge, slogan or credential with no issuing-source link |
| Money | Itemized costs and independent escrow instructions | Large advance payment to the agency without segregation details |
| Timing | Defined start, endpoint, range and update schedule | Guaranteed date without screening or compatibility conditions |
| Medical work | Named clinic and licensed decision-maker | Agency staff presented as making clinical-clearance decisions |
| Legal work | Independent counsel for each party | One lawyer described as representing everyone |
| Unexpected events | Written rematch, refund and contingency provisions | Important protections left to verbal assurances |
What are the limits of this guidance?
This report describes disclosure completeness in a specific captured dataset; it doesn’t evaluate whether any individual agency’s pricing is fair or competitive, only how much of it was itemized publicly.
This page provides general education, not legal, medical, tax or insurance advice. Regulations, policies, prices and clinical standards can change. Readers should obtain advice from professionals who know their facts, jurisdictions, clinic and insurance documents.
What does ‘complete pricing’ mean in the specific methodology this research used?
This research defined complete pricing as public disclosure of each major cost category discussed throughout this content package — agency fee, surrogate base compensation range, and an itemized or clearly bounded estimate of pass-through medical, legal, and insurance costs — available without requiring a personal consultation or direct inquiry to the agency. Under this definition, publishing only a single bundled total, or publishing some but not all of these categories, did not count as complete pricing for purposes of this study, which is a meaningfully stricter standard than simply having some pricing information publicly available.
Applying this specific, itemized-category standard rather than a looser standard (such as ‘publishes any pricing information at all’) is what produced this study’s headline finding regarding how few agencies in the broader dataset meet a genuinely complete, itemized public-pricing bar — a looser standard would likely show a higher percentage, but would also be less useful to a family trying to actually compare itemized costs across agencies before making initial contact.
Why does the gap between general pricing availability and complete itemized pricing matter for families?
A family relying on general pricing information (a single headline number, or a broad range) to narrow down agencies before deeper research risks eliminating or prioritizing agencies based on an incomplete picture — a lower headline number might reflect a genuinely lower-cost program, or might simply reflect a narrower published scope that excludes cost categories a competing agency’s higher headline number already includes. This is precisely the comparison trap this research is designed to help families avoid by highlighting how rarely a single public number actually represents the complete cost picture.
The practical implication for a family’s own research process is that requesting a complete, itemized written quote directly from every agency under serious consideration is not an optional extra step but a necessary one, given how uncommon complete public itemization is across the broader industry documented in this study — comparing agencies based on public materials alone, without this direct step, is comparing incomplete information by definition for the large majority of agencies in this dataset.
Did the research find any correlation between agency size or years in operation and pricing transparency?
The dataset does not show a strong or consistent correlation in either direction — some long-established, larger agencies in the dataset publish complete itemized pricing while others do not, and the same pattern holds among smaller and newer agencies, suggesting pricing-transparency practice is more a function of an individual agency’s specific business and marketing approach than of its size or tenure in the industry.
Would requiring complete pricing disclosure industry-wide be a realistic or desirable standard?
That is a policy question beyond this report’s research scope, which documents current practice rather than recommending regulatory changes — what this content package does recommend, regardless of any future industry-wide standard, is that individual families request complete itemized pricing directly from any agency under serious consideration, given how inconsistent public disclosure currently is.
Does publishing complete pricing correlate with any other consumer-protection practice this research series examined?
There is some overlap in the dataset between agencies publishing complete itemized pricing and agencies with verifiable independent escrow evidence, though the correlation is not strong enough to treat one as a reliable proxy for the other — each practice should be verified independently for any specific agency under consideration, consistent with this package’s general approach of not assuming one transparency practice implies another.
Why do so many agencies choose not to publish complete pricing on their websites?
Agencies that withhold complete pricing often cite the genuinely case-by-case nature of total program cost, which depends on surrogate compensation negotiated, number of transfer attempts, and legal complexity by state, as the reason a single published figure could be misleading — while this is a legitimate consideration, it is also true that a family cannot meaningfully comparison-shop without at least a representative range, which is why this study treats published pricing transparency as a meaningful evaluation criterion in its own right.
What does ‘complete’ pricing mean for purposes of this study’s methodology?
This study classified an agency as publishing complete pricing only if a prospective family could find, without needing to request a personal consultation first, a reasonably itemized breakdown covering agency fee, an estimated compensation range, and a general sense of additional costs such as legal and medical fees — a page that lists only a single vague starting figure without this breakdown was not counted as complete for purposes of this study.
How should a family interpret an agency that does not publish complete pricing?
Not publishing complete pricing is not automatically a red flag on its own, since some well-regarded agencies simply prefer a personal consultation to explain cost drivers accurately, but a family evaluating such an agency should ask directly, early in the conversation, for a written itemized estimate and treat any reluctance to provide one clearly and promptly as a more meaningful signal than the absence of a public price list alone.
Has pricing transparency across the industry improved or declined over recent years based on this study?
The broader industry trend has been gradually toward greater transparency, driven in part by increased family expectations shaped by transparency norms in other major financial decisions and by competitive pressure from agencies that have adopted transparent pricing as a differentiator — though as this study documents, a meaningful share of agencies still do not meet the complete-pricing standard, so transparency remains inconsistent rather than universal across the field.
Does this study distinguish between agencies that publish a range versus those that publish only a single average figure?
Yes — agencies publishing a genuine range (reflecting the real variation described elsewhere in this content package) were evaluated somewhat more favorably under this study’s transparency criteria than agencies publishing only a single average or ‘starting at’ figure, since a single number can understate the actual cost a specific family is likely to pay and may create a misleading first impression during the comparison-shopping stage.
What practical step can a family take when an agency’s published pricing seems too good to be true compared to others?
Ask directly what specifically is and is not included in the published figure — case management duration, number of included transfer attempts, and whether legal fee coordination is bundled are common places where an unusually low headline figure turns out to reflect a narrower scope of included services rather than a genuinely lower total cost.
Does published pricing transparency correlate with overall agency quality in this study?
This study did not find pricing transparency to be a reliable stand-alone predictor of overall agency quality, since some highly regarded agencies still prefer a consultation-first approach — transparency is best treated as one useful signal among several, alongside reviews, rematch policy, and escrow practices, rather than the single deciding factor.
What is the single most useful question a family can ask an agency that does not publish complete pricing?
Ask for a written, itemized cost breakdown before the first paid step in the process, and treat a prompt, clear response as a positive sign regardless of whether pricing appears publicly on the agency’s website.
Does this study make a recommendation to agencies themselves about pricing transparency?
The broader industry trend and this study’s findings both point toward published, itemized pricing as a meaningful trust-building practice, and agencies considering how to differentiate themselves in a competitive market may find that transparency itself becomes a genuine competitive advantage.
Is a lack of published pricing ever explained by state-specific regulatory restrictions rather than agency choice?
In a small number of cases, yes — certain state advertising or compensation-related regulations can affect what an agency is comfortable publishing publicly, which is worth keeping in mind before assuming withheld pricing always reflects a deliberate transparency choice.
Does third-party review sites or directories help fill the gap when an agency itself doesn’t publish pricing?
Independent directories and review platforms can sometimes offer general pricing insight gathered from other families’ experiences, though this information should be treated as a helpful starting point rather than a substitute for a direct, current, written estimate from the specific agency under consideration.
Is this study’s finding likely to hold steady, or is transparency expected to keep improving?
Transparency is expected to keep gradually improving as more families come to expect it and as competitive pressure rewards agencies that offer it clearly and upfront.
Frequently Asked Questions
Q. What is the main point of this pricing-completeness report?
A. About 38 percent of captured agencies published a total, but itemized components like surrogate compensation were almost never separately disclosed — request a fully itemized estimate rather than relying on a headline total.
Q. Who makes the final medical decision?
A. This report covers pricing-disclosure completeness; the receiving fertility clinic makes medical decisions separately.
Q. Does a published number guarantee my result?
A. No. Published prices, matching times, compensation ranges and outcome figures depend on definitions and individual circumstances.
Q. Why does independent escrow matter here?
A. It doesn’t directly determine pricing completeness — escrow is a separate financial safeguard, though both should be confirmed in writing.
Q. How should missing public information be interpreted?
A. Missing information means the research did not verify a comparable public disclosure, not that the true cost is higher or lower.
Q. Does FDA registration mean FDA approval?
A. No. Establishment registration is not approval, accreditation or endorsement.
Q. Does a published total include IVF and medication?
A. Not necessarily — confirm directly, since the study found these categories are inconsistently itemized even within published totals.
Q. Why did so few agencies separately disclose compensation?
A. Many bundle compensation into a total program figure rather than breaking it out publicly; request the itemized breakdown directly.
Q. What should I put in writing?
A. Put fees, exclusions, timing definitions, screening status, rematch terms, professional roles, escrow controls and dispute procedures in writing.
Q. Where can documented corrections be sent?
A. Send source-backed corrections to rankings@surrogacy4all.com.
About the Authors
Pooja Patel, MD – MBBS, Seth G.S. Medical College and K.E.M. Hospital; Fellowship in Embryology; Manager, Surrogacy4All. Medically reviewed by Rashmi Gulati, MD – Board Certified, Internal Medicine; Medical Advisor, Surrogacy4All; privileges at Mount Sinai Hospital. Meet the team at Our team.
Related Surrogacy Resources
Talk With a Physician-Led Team
Request a free consultation and a written review of costs, matching, screening and next steps. Call (212) 661-7673 or email info@surrogacy4all.com.
Methodology and Disclosure
This page is produced by DGA, Inc. (Surrogacy4All), which provides surrogacy services and may benefit commercially if a reader chooses the agency. No agency pays for placement in the Surrogacy4All rankings. Comparative statements describe the stated methodology and available evidence; they are not government endorsements, independent awards or guarantees.
The framework is part of an active research program associated with the manuscript The U.S. Surrogacy Agency Market 2027: Services, Transparency and Consumer Protection, Baloch K and Saghar V. The data table and rubric are available on request. Missing data are labeled unverified rather than treated as zero.
Send documented corrections to rankings@surrogacy4all.com.
Sources
- ASRM recommendations for practices using gestational carriers
- New York State Child-Parent Security Act and licensed programs
- FDA donor-eligibility guidance under 21 CFR Part 1271
- SART National Summary Report
- CDC National ART Summary
- Surrogacy4All Research and Data
Dr. Pooja Patel
Dr. Pooja Patel is a Manager of Surrogacy program at Surrogacy4all. She has 10 years of experience in Anesthesiology and critical care medicine.
She received her medical degree from Seth GS Medical College and K.E.M Hospital in India. She then completed an internship. She finished her Anesthesia residency at Grant Govt Medical College and JJ Group of Hospitals in India.
- Dr. Pooja Patel
- Dr. Pooja Patel
- Dr. Pooja Patel
- Dr. Pooja Patel
